Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

BioMarin Sinks as FDA Approval Pushed Until At Least 2022

Published 08/19/2020, 12:32 PM
Updated 08/19/2020, 12:33 PM

By Christiana Sciaudone

Investing.com --  BioMarin Pharmaceutical Inc (NASDAQ:BMRN) slumped more than 36% on Wednesday after the U.S. Food and Drug Administration rejected its gene therapy for hemophilia A. 

It's not the end of the world for the drug, though. The FDA cited the need for longer-term data, which could push approval -- if it comes at all -- to 2022.  

All signs pointed to approval this month after clinic trials showed it reduced the bleeding rate of patients with the disorder, decreasing or eliminating the need for treatment, Reuters reported. 

The market for the drug is not especially large. There are about 16,000 patients in the U.S. with hemophilia A in which they are missing the factor VIII clotting protein. The gene therapy would allow them to forego standard therapy requiring patients to infuse factor proteins into their bloodstreams several times a week for life, costing hundreds of thousands of dollars a year, according to Reuters.  

BioMarin had said the gene therapy could be priced in a range of $1 million to $3 million, making it the most expensive one-time treatment, Reuters said.  

The stock has 17 buy ratings, four holds and no sells.      

 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.